Treatment Outcome of Combination Therapy Including Clarithromycin for Mycobacterium avium Complex Pulmonary Disease |
Kim, Eun-Young
(Department of Internal Medicine, Chonnam National University Hospital)
Chi, Su-Young (Department of Internal Medicine, Chonnam National University Hospital) Oh, In-Jae (Department of Internal Medicine, Chonnam National University Hospital) Kim, Kyu-Sik (Department of Internal Medicine, Chonnam National University Hospital) Kim, Yu-Il (Department of Internal Medicine, Chonnam National University Hospital) Lim, Sung-Chul (Department of Internal Medicine, Chonnam National University Hospital) Kim, Young-Chul (Department of Internal Medicine, Chonnam National University Hospital) Kwon, Yong-Soo (Department of Internal Medicine, Chonnam National University Hospital) |
1 | Hasegawa N, Nishimura T, Watabnabe M, et al. Concentrations of clarithromycin and active metabolite in the epithelial lining fluid of patients with Mycobacterium avium complex pulmonary disease. Pulm Pharmacol Ther 2009;22:190-193. DOI ScienceOn |
2 | Kobashi Y, Matsushima T. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study. Respiration 2007;74:394-400 DOI ScienceOn |
3 | Hasegawa N, Nishimura T, Ohtani S, et al. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease. Chest 2009;136:1569-1575. DOI ScienceOn |
4 | Fujikane T, Fujiuchi S, Yamazaki Y, et al. Efficacy and outcomes of clarithromycin treatment for pulmonary MAC disease. Int J Tuberc Lung Dis 2005;9:1281-1287. |
5 | Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999;160:866-872. DOI ScienceOn |
6 | Lam PK, Griffith DE, Aksamit TR, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006;173:1283-1289. DOI ScienceOn |
7 | Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997;156(2 Pt 2):S1-S25. DOI ScienceOn |
8 | Koh WJ, Kwon OJ, Jeon K, et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006;129:341-348. DOI ScienceOn |
9 | Lee JY, Choi HJ, Lee H, et al. Recovery rate and characteristics of nontuberculous mycobacterial isolates in a university hospital in Korea. Tuberc Respir Dis 2005;58:385-391. DOI |
10 | Choi SP, Lee BK, Min JH, Kim JH. Pathogenic classification and clinical characteristics of nontuberculous mycobacterial pulmonary disease in a National Tuberculosis Hospital. Tuberc Respir Dis 2005;59:606-612. DOI |
11 | Koh WJ, Kwon OJ. Diagnosis and treatment of nontuberculous mycobacterial lung disease. Korean J Med 2008;74:120-131. |
12 | Jeon K, Koh WJ, Kwon OJ, et al. Usefulness of bronchoscopy for the diagnosis of nontuberculous mycobacterial pulmonary disease. Tuberc Respir Dis 2004;57:242-249. DOI |
13 | Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416. DOI ScienceOn |
14 | Korean Academy of Tuberculosis and Respiratory Disease. Guidelines for the management of tuberculosis. Seoul: Korean Academy of Tuberculosis and Respiratory Disease, 2005. |
15 | Koh WJ, Kwon OJ, Kang EH, et al. Treatment of Mycobacterium avium complex (MAC) pulmonary disease. Tuberc Respir Dis 2004;57:234-241. DOI |
16 | Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161(4 Pt 1):1376-1395. DOI ScienceOn |
17 | Kee SJ, Kim SM, Kim SH, et al. Multiplex PCR assay for identification of mycobacterial species isolated from liquid cultures. Chonnam Med J 2009;45:19-26. DOI ScienceOn |
18 | Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS: Clarithromycin Study Group of France. Chest 1995;107:1035-1040. DOI ScienceOn |
19 | Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996;153(6 Pt 1):1766-1772. DOI ScienceOn |
20 | Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 2004;126:566-581. DOI ScienceOn |
21 | Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to highdose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993;16:215-221. DOI ScienceOn |
22 | Carter G, Young LS, Bermudez LE. A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. Antimicrob Agents Chemother 2004;48:4907-4910. DOI ScienceOn |
![]() |